Objective: To document the use of psychotropic drugs in Quebec older adult population with a depressive or anxiety disorder.
A ccording to results from the ESA study, the prevalence of depression and anxiety disorders is 12% in the older adult population living at home in Quebec, 1 and the average length of an episode of a mood or an anxiety disorder was estimated at 23.4 months. 2 Further, among the respondents with a mood or an anxiety disorder only 19.2% persisted into the following year. 3 The pharmacological treatment for mood and anxiety disorders included ADs and BDZs. [4] [5] [6] [7] It has been reported that 32% of Quebec's older adult population living at home uses an MDD of 6.1 mg of equivalent diazepam for an average of 205 days per year 8 ; the proportion of BDZ users being around 9% in the general adult population. 9, 10 The ESA study results also indicate that, in 2005, 17.3% of community-dwelling older adults used ADs for 409 days on average during the 24-month period preceding the survey, which is a higher proportion than the one (6.3%) observed in 2000. 11 Although the use of ADs has increased substantially in recent years, the effectiveness of these medicines is still questioned. [12] [13] [14] [15] [16] To our knowledge, few data are available on the pattern of use of psychotropic drugs in the older adult population with a mood or an anxiety disorder and no study was found regarding older adult patients living in a managed care system where most medical services are free, as it exists in the province of Quebec. Because of the rapid aging population in the next 20 years and the potential burden on public finances to pay for the services required by the older adult population with mental health needs, it is essential to provide clinicians and health care decision makers with conclusive data regarding the population effectiveness of AD and BDZ use in this population.
Our study examined patterns of AD and BDZ use according to mental health status and sex, because the use of psychotropic drugs is twice as prevalent among older women than among men in Quebec, 11, 17, 18 as well as elsewhere. [19] [20] [21] [22] [23] For our study, respondents having a medical diagnosis of depression or anxiety were compared with those having a probable depression or anxiety disorder according to responses to the ESA-Qs; as well as to respondents not having reported any symptoms of depression or anxiety during a 2-year follow-up period.
Method
Data used in our study came from the 2-year longitudinal ESA study conducted between 2005 and 2008 using a probabilistic sample (n = 2811) of French-speaking community-dwelling older adults (94% of the population of Quebec speak French). A random digit dialling method was used to develop the sampling frame of the study. A random sampling method was also used to select only one older adult (aged 65 years or older) within the household. The response rate for this study was 78.5% at T1, and 79.1% of the respondents at T1 participated in the follow-up interview 12 months later.
Procedure
Data were collected as follows: a health professional contacted the potential respondents by phone to describe the objectives and the length of the study, answer their questions, and ask them to participate in an in-home interview. Respondents were offered $30 for their participation at the baseline and follow-up interviews.
The in-home interviews, which lasted 90 minutes on average, took place within 2 weeks of initial contact. Written consent to conduct the interview was obtained at the beginning of the interview from all volunteers. People presenting severe or moderate cognitive problems based on the Mini-Mental State Examination (a score of less than 22) were excluded at the beginning of the interview. [24] [25] [26] [27] Respondents were asked to participate in a similar in-home interview 12 months later. At the end of each interview, respondents were invited to give a written consent to obtain data on their use of health and pharmaceutical services for the preceding and following years from the RAMQ (Quebec's health insurance plan). For those who accepted (n = 2503), data from the ESA survey were paired with individual information from the RAMQ's medical and pharmaceutical services registers using the respondent's health insurance number. A success rate of 99.6% (n = 2494) was obtained in the matching of the data. The RAMQ file contains all claims for medical services paid for by Quebec's medicare system. The pharmaceutical services register contains the code of the medicine prescribed, the quantity, the dosage, the dates of distribution, as well as the length of treatment. In our study, 490 subjects who did not participate in both times of the ESA survey were excluded from the study. In addition, 135 people who were not covered by RAMQ during the year preceding the ESA interview were also excluded from the study. Overall, 1869 people were included in our study, including 279 (14.9%) respondents with a depression or an anxiety disorder according to the ESA study results, and 283 (15.1%) respondents with a depression or an anxiety disorder according to the RAMQ register. These prevalence rates are similar to those observed in the older adult 
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Measures
The respondent's use of BDZs was measured for the 12-month period preceding (T0 to T1) and following (T1 to T2) the date of their first ESA interview (T1). Two indicators were used: the MDD (received) index and the number of days of BDZ use during the 24-month period studied. The MDD index was constructed calculating the number of BDZ doses received during the studied period (24 months) divided by the length of exposure. The length of exposure corresponds to the number of days during the 2-year period where the respondents were not hospitalized or institutionalized. To take into account the different dosage received, BDZ use was analyzed by transforming the various molecules prescribed in the daily dose of the diazepam equivalent (in milligrams). 29 For our study, the duration of BDZ use was constructed as a continuous variable representing the number of days where BDZs were prescribed during the 24-month period studied.
The respondent's use of ADs was also measured for the 12-month period preceding and following the date of the respondents' first interview (T1). Two indicators were used: the PDD-DDD index, and the number of days of AD use during the 24-month period studied. The PDD index represents a multiple of the DDD used on average by the AD users. The PDD in milligrams of each specific AD were converted into multiples of the DDD index, dividing the PDD of the AD by the DDD for the drug (PDD-DDD). The DDD is a statistical measure of a drug defined in reference to the assumed average maintenance dose per day, used for its main indication in adults weighting 70 kg on average. 30 The PDD-DDD ratios were summed during the 24-month period studied and the total was divided by the number of prescriptions during this period. Further, for our study, the duration of AD use was constructed as a continuous variable representing the number of days where ADs were prescribed during the 24-month period studied.
The respondent's physical health status was measured using the chronic disease score. The chronic disease score is a comorbidity index, weighted for disease severity and derived from medication data. 31 This index has been validated for older adults and is a good indicator for general physical health status. 32 For our study, the score obtained was used as a continuous variable.
The respondent's mental health status was measured at T1 for the 12-month period preceding their first ESA interview (T0 to T1) and again at T2 for the same preceding 12 months (T1 to T2). The respondent's mental health status was measured using the ESA diagnostic component of the ESA-Qs developed by the research team based on DSM-IV criteria. 33 The ESA diagnostic component is similar to the Diagnostic Interview Schedule and the Composite International Diagnostic Interview, which have demonstrated satisfactory reliability and validity. [34] [35] [36] [37] [38] [39] [40] In our study, the 12-month period diagnosis was made for the following psychiatric disorders: major depression, minor depression, mania, specific phobia, social phobia, agoraphobia, panic disorder, obsessive-compulsive disorder, and generalized anxiety disorder. The complete definition of the disorders studied has been reported in a previous paper. 1 For our study, subjects were also classified according to the mental health diagnosis codes (ICD-9) 41 reported by their doctor in their payment request to the RAMQ. The ICD-9 codes used were restricted to mood and anxiety disorders 1 corresponding to the mental health disorders studied in the ESA survey ( Table 2 ). In addition, 5 groups of subjects were defined using the ESA survey data: Group 1 included respondents with a probable depression or anxiety disorder at T1 in total remission at T2; Group 2 included respondents in partial remission at T2; Group 3 included respondents having a persistent probable depression or anxiety disorder at T2, Group 4 included subjects having a probable incident disorder at T2; and Group 5 included subjects without any symptom at T1 and T2. Full remission subjects were those who met DSM-IV criteria for one of the psychiatric disorders studied at the baseline interview and did not report any symptoms related to the same psychiatric disorder at the follow-up examination 12 months later. Partial remission was defined as a decrease of symptoms below DSM-IV criteria at the follow-up examination. Persistent subjects included those who presented symptoms meeting DSM-IV criteria for one of the psychiatric disorders studied at both the baseline and the follow-up interview 12 months later. Incident subjects were defined as those who did not report symptoms meeting DSM-IV criteria for one of the psychiatric disorders studied at the baseline interview but reported symptoms of an active psychiatric disorder at the follow-up examination 12 months later. 2, 3 The disease-free group was defined as subjects who participated in T1 and T2 but did not report any symptoms for any of the psychiatric disorders studied at both times.
Analyses
Data were weighted to ensure that the true proportions of older adults in each region and each geographical area were reflected in the analysis. In our study, 20.9% of the respondents at T1 did not participate in the follow-up interview at T2. Results showed that respondents lost to follow-up were more likely to have used health services for their psychological distress symptoms (OR 1.30; 95% CI 1.03 to 1.64). The results also showed that loss to follow-up was not associated with the presence of a DSM-IV disorder (OR 0.93; 95% CI 0.78 to 1.12).
A logistic regression analysis controlling for sex, age, and respondent's physical health status was carried out to determine the associations between mental health status (persistent, compared with partial or total remission) and the number of days of AD or BDZ use during the 24-month period studied. 42 The odds ratio and confidence intervals were used as a measure of association. All hypotheses were tested at the 95% significance level.
Results
Based on the weighted sample (Table 1) , the respondents' mean age was 73.8 years (SD 6.1): 58.0% of the respondents were women and 14.9% of the respondents presented with a depressive or an anxiety disorder according to DSM-IV criteria.
As As Table 2 indicates, 46.9% of patients with depression or an anxiety disorder, according to the RAMQ register, were prescribed an average of 400 days (12.9 months) of ADs during this period. The mean PDD was 1.5 times higher than the World Health Organization's DDD index. Also, among patients with a mental disorder identified through the RAMQ administrative database, 58.7% were prescribed an MDD of 5 mg of diazepam equivalent for 338 days (10.9 months) on average during the 24-month period studied. Nearly 29% of the RAMQ patients with a mental disorder used ADs and BDZs during the 24-month period. The length of use of these psychotropic drugs during this period was 260 days on average.
Regarding AD use, similar results were observed among the 279 respondents having had a depression or an anxiety disorder during the 24-month period studied according to the ESA survey results. In this group, the duration of AD use was not lower in the ESA respondents group than in the RAMQ patients group (t = 0.33, df = 235, P = 0.74) also the PDD-DDD ratio was similar (t = 0.00, df = 235, P = 0.99).
In addition, the BDZ MDD index (t = 0.94, df = 1, P = 0.04) and the duration of BDZ use (t = 1.91, df = 307, P = 0.06) were not statistically different in the ESA respondents with a mental disorder group or in the RAMQ patients group. However, the results showed a higher proportion of AD users among subjects with mood disorders, compared with anxiety disorders, according to the ESA group definition (c² = 7.11, df = 1, P = 0.01) while, anxiety disorder subjects presented a longer duration of AD use (t = 2.01, df = 75, P = 0.05). Further, no significant difference was observed in the proportion of BDZ users (c² = 0.05, df = 1, P = 0.83) and in the duration of BDZ use (c² = 1.25, df = 1, P = 0.21) between respondents with mood and anxiety disorders according to the ESA classification.
When the analyses were restricted to subjects having a RAMQ mental health disorder and an ESA mood or anxiety disorder (n = 62), no difference was observed in the duration of AD use (t = 0.16, df = 172, P = 0.87), in the PDD-DDD ratio (t = 0.67, df = 172, P = 0.50), in the MDD index (t = 0.98, df = 203, P = 0.33), and in the duration of BDZ use (t = 0.73, df = 203, P = 0.46), compared with results observed in the RAMQ patients group. As Table 2 indicates, 10.0% of the respondents without any symptoms (ESA) at T1 and at T2 and any RAMQ depression and anxiety diagnosis between T0 and T2 were AD users during the 24-month period studied. They represent 26.2% of the AD users and consumed ADs for 494 days (15.9 months) on average during the 24-month period studied. In this group, the AD PDD-DDD index was not lower than in the RAMQ patients group (t = 1.66, df = 222, P = 0.10) than for the depression or anxiety ESA group (t = 1.46, df = 193, P = 0.15), while their duration of AD use was higher compared with the 2 groups, respectively (RAMQ group: t = 2.62, df = 222, P = 0.01; ESA group: t = 2.66, df = 193, P = 0.01). Our results also showed that this group, which represents 36.5% of BDZ users, consumed BDZs for 351 days (11.3 months) on average during the 24-month period studied. In this group, the BDZ MDD index and the duration of BDZ use did not differ between the RAMQ patients with a mental disorder (MDD index: t = 0.14, df = 409, P = 0.89, duration of use: t = 0.48, df = 409, P = 0.63) and those in the ESA mental disorder group (MDD index: t = 1.58, df = 386, P = 0.11, duration of use: t = 1.27, df = 386, P = 0.20).
As Table 3 indicates, the proportion of AD users in the persistent group (50%) was higher than the one observed for the total remission group (c² = 6.18, df = 1, P = 0.02) but not for the partial remission group (c² = 0.73, df = 1, P = 0.39).
In addition, no difference was observed in the mean duration of AD use between the persistent and the total remission group ([Kruskal Wallis] c² = 0.09, df = 1, P = 0.76) or the partial remission group ([Kruskal Wallis] c² = 0.50, df = 1, P = 0.48). Also, no difference was observed in the mean duration of BDZ use among users between the persistent and total remission groups ([Kruskal Wallis] c² = 3.63, df = 1, P = 0.06), or partial remission group ([Kruskal Wallis] c² = 3.18, df = 1, P = 0.08).
As Table 4 indicates, women were more likely than men to be in total or partial remission after 24 months. However, when the effect of the respondent's sex, age, and physical health status was controlled, no evidence was found that the probability to be in partial or total remission, as compared with the persistent group, was associated with the number of days of AD use or the number of days of BDZ use during the 24-month period studied. 
Discussion
In our study, the prevalence rates of BDZ or AD users were 35.9% and 18.5%, respectively. These prevalence rates are similar to those observed in the older adult general population in Quebec. 8, 43 Only 46.9% of the patients having had a depression or an anxiety diagnosis during the 24-month period studied according to the RAMQ register used ADs for 400 days (12.9 months) on average during this period. This is concordant with results 44 indicating that only 30% of subjects with an MDE during the preceding 12 months took ADs. Also, nearly 59% of patients with a mental health disorder according to the RAMQ used an MDD of 5 mg of diazepam equivalent for 338 days (10.9 months) on average during the 24-month period studied. The BDZ MDD index and the duration of BDZ use were not statistically different in the ESA and RAMQ groups. Results also showed no evidence of a significant difference in the proportion of AD users and in the duration of AD use, as well as in the proportion of BDZ users and in the duration of BDZ use between subjects with a mood or anxiety disorder according to ESA results, suggesting that the ESA respondents with a mental disorder were as severe as subjects from the RAMQ patients group.
However, 10% of the subjects without any symptoms (ESA) at T1 and at T2 and a RAMQ depression or anxiety diagnosis between T0 and T2 used ADs during the 24-month period studied. They represent 26.2% of AD users and consumed these drugs for 494 days (15.9 months) on average during the 24-month period studied. In this group, the AD PDD-DDD index and the duration of AD use was higher than in both the RAMQ or the ESA group. This result is consistent with findings 45 where a significant proportion of AD users did not report past-year MDEs. One possible explanation is that subjects in this group may have a lifetime history of depression or anxiety disorder for which long-term AD use was prescribed. The prevalence of such situations reported in other studies is about 11% for depressive disorders 46, 47 and 16% for anxiety disorders. 48 Our results also showed that this group, which represents 36.5% of the BDZ users, consumed BDZ for 351 days (11.3 months) on average during the 24-month period studied. In this group, the MDD index and the duration of BDZ use was not lower than in the RAMQ patients' group. The prevalence rate of BDZ users (27%) observed in this group is close to the prevalence observed (32%) in the general older adult population. 8 No difference was observed in the duration of AD use between the persistent group and the total or the partial remission group. Also, no significant difference was observed in the length of BDZ use between the persistent and the total or the partial remission group. One possible explanation is that total and partial remission groups had less severe cases.
Limitations
The results of our study should be viewed in light of certain limitations. First, BDZ and AD use was assessed using data on drugs dispensed, which may differ from those consumed. Second, our data did not allow us to control for indications of the medicines prescribed. This may have impacted our results as these drugs may have been prescribed for nonpsychiatric conditions. Despite these limitations, the ESA survey is the first longitudinal Quebec study providing 
Conclusion
When the effect of the respondent's sex, age, and physical health status was controlled, no evidence was found that the probability to be in partial or total remission, compared with the persistent group, was associated with the duration in months of AD and BDZ use during the 24-month period studied. The results of our study question the population effectiveness of these drugs in the elderly population living in the community. Future research should focus on studying new episodes of mental illness in the older adult population and on factors related to adherence to treatment. Current medical prescribing practices should be made available to physicians to help clinicians and decision makers to improve performance of the health care system. Résultats : Nos résultats indiquent que seulement 46,9 % des sujets ayant un diagnostic de dépression ou d'anxiété selon le registre de la Régie de l'assurance maladie du Québec (RAMQ) utilisaient des antidépresseurs 400 jours (12,9 mois) en moyenne durant la période de 24 mois étudiée. En outre, 59 % des sujets ayant un trouble de dépression ou d'anxiété selon la RAMQ utilisaient une dose quotidienne moyenne de 5 mg d'équivalent diazépam 338 jours (10,9 mois) en moyenne pendant la même période. Cependant, 10,0 % des sujets sans aucun symptôme (ESA) à T1 et T2 et aucun diagnostic de dépression ou d'anxiété selon la RAMQ entre T0 et T2 étaient des utilisateurs d'antidépresseurs au cours de la période de 24 mois étudiée. Ils représentent 26,2 % des utilisateurs d'antidépresseurs et consommaient ces médicaments 494 jours (15,9 mois) en moyenne au cours de la période étudiée. Finalement, le nombre de jours d'utilisation d'antidépresseurs et de benzodiazépines n'était pas associé à une rémission partielle ou totale.
Conclusions :
Ce résultat remet en question l'efficacité-population de ces médicaments dans cette population.
